News | June 30, 2024
Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals
Laurus Labs receives EIR from USFDA for API facilities
Laurus Labs receives EIR from USFDA for API facilities
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
The facility was inspected from May 7 to May 17, 2024
Renews GMP certifications for India and Malaysia sites
_256_384.jpg)
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
There was no observation related to data integrity reported
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Lupin updates on shipment of Mirabegron ER Tablets
Subscribe To Our Newsletter & Stay Updated
